Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005).

Zhang Y, Wang L, Zhang R, Qi P, Xie J, Shi H, Lin W, Wu Y, Yu J, Fan J, Feng G, Zheng H, Wu M.

Pediatr Hematol Oncol. 2019 Oct;36(7):399-409. doi: 10.1080/08880018.2019.1621971. Epub 2019 Sep 18.

PMID:
31530209
2.

Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.

Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, Shao ZH, Ren HY, Hu JD, Xu KL, Wang JW, Song YP, Fang MY, Li J, Yan XY, Huang XJ.

Lancet Oncol. 2018 Jul;19(7):871-879. doi: 10.1016/S1470-2045(18)30295-X. Epub 2018 Jun 5.

PMID:
29884593
3.

Long-term survey of outcome in acute promyelocytic leukemia.

Hu J, Shen Z, Sun H, Wu W, Li X, Sun G, Wang Z.

Chin Med J (Engl). 2000 Feb;113(2):107-10.

PMID:
11775530
4.

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Lima AS, Ruiz-Argüelles G, Undurraga MS, Martinez L, Kwaan HC, Gallagher R, Niemeyer CM, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Ann Hematol. 2014 Dec;93(12):2001-10. doi: 10.1007/s00277-014-2142-9. Epub 2014 Jul 2.

PMID:
24981688
5.

[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].

Xu SN, Chen JP, Liu JP, Xia Y.

Zhong Xi Yi Jie He Xue Bao. 2009 Nov;7(11):1024-34. doi: 10.3736/jcim20091102. Review. Chinese.

PMID:
19912733
6.

Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.

Hong SD, Kim YK, Kim HN, Lee SR, Ahn JS, Yang DH, Lee JJ, Lee IK, Shin MG, Kim HJ.

Korean J Hematol. 2011 Mar;46(1):24-30. doi: 10.5045/kjh.2011.46.1.24. Epub 2011 Mar 15.

7.

Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.

Lou Y, Tong H, Yu W, Wei J, Xu W, Mao L, Jin J.

Leuk Res. 2019 Aug;83:106168. doi: 10.1016/j.leukres.2019.106168. Epub 2019 Jun 8.

PMID:
31202077
8.

Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.

Cheng Y, Zhang L, Wu J, Lu A, Wang B, Liu G.

Eur J Haematol. 2013 Dec;91(6):483-9. doi: 10.1111/ejh.12194. Epub 2013 Sep 17.

PMID:
24033687
10.

Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.

Kutny MA, Alonzo TA, Gerbing RB, Wang YC, Raimondi SC, Hirsch BA, Fu CH, Meshinchi S, Gamis AS, Feusner JH, Gregory JJ Jr.

J Clin Oncol. 2017 Sep 10;35(26):3021-3029. doi: 10.1200/JCO.2016.71.6183. Epub 2017 Aug 2.

11.

Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.

Testa U, Lo-Coco F.

Ann Hematol. 2016 Apr;95(5):673-80. doi: 10.1007/s00277-016-2622-1. Epub 2016 Feb 26. Review.

PMID:
26920716
12.
13.

Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia.

Wu F, Wu D, Ren Y, Duan C, Chen S, Xu A.

Oncotarget. 2016 Jul 26;7(30):47319-47331. doi: 10.18632/oncotarget.10118.

14.

Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia.

Yoo ES.

Korean J Pediatr. 2011 Mar;54(3):95-105. doi: 10.3345/kjp.2011.54.3.95. Epub 2011 Mar 31.

15.

[Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia].

Wang J, Huang JB, Liu ZL, Zhang BH, Xu HG, Xue HM, Chen C.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Dec;25(6):1605-1610. doi: 10.7534/j.issn.1009-2137.2017.06.004. Chinese.

PMID:
29262883
16.

Outcome of childhood acute promyelocytic leukemia treated using a modified AIDA protocol.

Kim MH, Choi CS, Lee JW, Jang PS, Chung NG, Cho B, Jeong DC, Kim HK.

Korean J Hematol. 2010 Dec;45(4):236-41. doi: 10.5045/kjh.2010.45.4.236. Epub 2010 Dec 31.

17.

Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy.

Lou Y, Lu Y, Zhu Z, Ma Y, Suo S, Wang Y, Chen D, Tong H, Qian W, Meng H, Mai W, Yu W, Xu W, Wang L, Mao L, Pei R, Jin J.

Hematol Oncol. 2018 Jun 3. doi: 10.1002/hon.2519. [Epub ahead of print]

PMID:
29862538
18.

Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.

Yang MH, Wan WQ, Luo JS, Zheng MC, Huang K, Yang LH, Mai HR, Li J, Chen HQ, Sun XF, Liu RY, Chen GH, Feng X, Ke ZY, Li B, Tang YL, Huang LB, Luo XQ.

Am J Hematol. 2018 Dec;93(12):1467-1473. doi: 10.1002/ajh.25271. Epub 2018 Oct 20.

19.

[Efficacy analysis of sequential treatment with chemotherapy, ATRA and As(2)O(3) for acute promyelocytic leukemia].

Ma XJ, Ren HY, Cen XN, Qiu ZX, Wang WS, Ou JP, Wang Y, Xu WL, Li Y, Wang MJ, Wang LH, Dong YJ, Yin Y, Liang ZY.

Zhonghua Xue Ye Xue Za Zhi. 2010 May;31(5):328-32. Chinese.

PMID:
21122313
20.

Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.

Ghavamzadeh A, Jalili M, Rostami S, Yaghmaie M, Aliabadi LS, Mousavi SA, Vaezi M, Fumani HK, Jahani M, Alimoghaddam K.

Leuk Res. 2018 Mar;66:85-88. doi: 10.1016/j.leukres.2018.01.019. Epub 2018 Feb 3. Erratum in: Leuk Res. 2018 Apr;67:116.

PMID:
29407588

Supplemental Content

Support Center